589 related articles for article (PubMed ID: 26559549)
1. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
[TBL] [Abstract][Full Text] [Related]
2. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
[TBL] [Abstract][Full Text] [Related]
3. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
4. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
Pierart F
Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
[TBL] [Abstract][Full Text] [Related]
5. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
Farinde A
Nurse Pract; 2015 Jul; 40(7):16-7. PubMed ID: 26080292
[No Abstract] [Full Text] [Related]
6. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
[TBL] [Abstract][Full Text] [Related]
7. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Somayaji R; Parkins MD
Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
[TBL] [Abstract][Full Text] [Related]
8. Eradication of
Akkerman-Nijland AM; Yousofi M; Rottier BL; Van der Vaart H; Burgerhof JGM; Frijlink HW; Touw DJ; Koppelman GH; Akkerman OW
Ther Adv Respir Dis; 2020; 14():1753466620905279. PubMed ID: 32046620
[TBL] [Abstract][Full Text] [Related]
9. Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
Tappenden P; Harnan S; Uttley L; Mildred M; Carroll C; Cantrell A
Health Technol Assess; 2013 Dec; 17(56):v-xvii, 1-181. PubMed ID: 24290164
[TBL] [Abstract][Full Text] [Related]
10. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K
Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264
[TBL] [Abstract][Full Text] [Related]
11. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
12. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
13. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
Chuchalin A; Amelina E; Bianco F
Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
[TBL] [Abstract][Full Text] [Related]
14. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
[TBL] [Abstract][Full Text] [Related]
15. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.
Hamed K; Debonnett L
Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103
[TBL] [Abstract][Full Text] [Related]
16. Use of inhaled tobramycin in cystic fibrosis.
Shteinberg M; Elborn JS
Adv Ther; 2015 Jan; 32(1):1-9. PubMed ID: 25620537
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Stass H; Delesen H; Nagelschmitz J; Staab D
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
[TBL] [Abstract][Full Text] [Related]
18. The use of tobramycin for Pseudomonas aeruginosa: a review.
Fiel SB; Roesch EA
Expert Rev Respir Med; 2022 May; 16(5):503-509. PubMed ID: 35320051
[TBL] [Abstract][Full Text] [Related]
19. Inhalation of tobramycin using simulated cystic fibrosis patient profiles.
Haynes A; Geller D; Weers J; Ament B; Pavkov R; Malcolmson R; Debonnett L; Mastoridis P; Yadao A; Heuerding S
Pediatr Pulmonol; 2016 Nov; 51(11):1159-1167. PubMed ID: 27133552
[TBL] [Abstract][Full Text] [Related]
20. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
